Raj may be highlighting Renazorb due to the lack-luster results reported by KERX for their product. That leaves Renazorb as the competitor to be developed.
The KERX binder "Zerenex" has been panned by Adam Feuerstein today which certainly should add interest in Spectrum's Renazorb (SPI-014) which is being offered for sale by the company. It's an oral tablet which has shown good results in a P2 study - an another undervalued gem in the company pipeline.
Nothing remarkable about the report. Earnings near nil as expected and clinical trial results not expected until late in the year. Company has enough funds to carry them till 2016.
Found report that PRX-105 passed the P1 trial and a Nov 2011 release on possible role of AChE-R in the brain's protective mechanisms. The research highlights that a splice shift, either inherited or induced by environmental factors (e.g. neurotoxins), from the more common 'synaptic form' of acetylcholinesterase (AChE-S) to the monomeric 'read-through' variant of AChE (AChE-R), is important in conferring protection against Parkinson-like symptoms. Furthermore, intravenous injection with PRX-105 induced a protective gene expression profile in the striatum of the brain. "Adaptive alternative splicing correlates with less environmental risk of Parkinsonism," has been published online in the Journal of Neurodegenerative Diseases, reported scientists from the Hebrew University of Jerusalem, Israel and Protalix BioTherapeutics. Company continued listing 105 until a year ago.
Given the war with Hamas and chemical weapons use in Syria, the absence of any acetylcholinesterase for Biodefense (PRX-105) news seems odd, and it is no longer listed among products in development. The last news was the announcement of a P1 trial on May 17, 2010. Anyone know what happened to it?
PLX has no reason for seeking redemption as their plan is not flawed. Results coming in the next five months will invigorate share price, imho. As for Ebola antibodies, the PLX system could be applied given the right genetic additions, but others are already their so your suggestion is a lame distraction, shortie.
A striking resemblance of bladder cancer to an aggressive subtype of breast cancer scientists call "basal-like" or "triple negative" lung tumors was found on the molecular level. In the triple-negative breast tumors, named as such because they lack the three hormone receptors targeted by the most successful therapies, researchers learned the molecular wiring looked so different from any other breast cancers that they think the disease may warrant a new classification. Therapies used for the bladder may be advised for it say Dr. Christopher Benz and Christina Yau of the Buck Institute.
For completeness, Ken bought an additional 10,000 shares at $10.95 on Oct. 12, 2012 and received a 30,000 share bonus on Dec. 3, 2013. All told, he left the company holding 100,000 shares and some 140,000 option shares priced at $12.01 which I doubt he has exercised (has until 2022 to do so). I don't feel sorry for Ken.
Not so, mutton-mouth. He was given a generous salary, relocation dollars and lots of option shares (half of which he lost by leaving early). Get your facts straight:
In connection with his employment, Mr. Keller entered into an at-will employment agreement with the Company. Pursuant to the terms of the agreement, he is eligible to receive a base salary of $525,000 per year and an annual performance-based bonus of up to 50% of such salary. During Mr. Keller’s relocation period (up to six months), he is entitled to receive up to $3,500 per month reimbursement for reasonable and necessary travel and temporary living expenses. Once his relocation is complete, Mr. Keller is entitled to receive an additional one-time relocation bonus of $30,000.
In accordance with the terms of his employment agreement, Mr. Keller has also been granted 300,000 stock options at an exercise price per share equal to the closing sales price of the Company’s common stock on September 7, 2012, or $12.01. The stock options have a ten-year term and 25% vest on the first anniversary of the grant date, with the remaining shares to vest in equal monthly amounts over a three-year period thereafter. Mr. Keller has also been granted (i) 20,000 restricted stock awards, to vest 50% upon the completion of six months employment and the other 50% upon the completion of one year of employment, and (ii) 100,000 restricted stock awards, to vest 25% upon the completion of one year of employment and the remaining 75% to vest in equal annual amounts over a three-year period thereafter. The grants and awards described above were made under, and are subject to the terms of, the Company’s 2009 Incentive Award Plan.
Ken Keller bought 8,000 shares at ca. $12,50 on Sept 7, 2012 and has yet to sell any shares.
The usual long winded SA dump to scare investors. Spectrum has filed counter suits to an early generic and they make a well reasoned defense. Will be tied up in court for some time to come before any generic appears. If one does appear, Spectrum will still have the market though the margins may be reduced.
registration statement on Form S-8 (the “Registration Statement”) of an additional 848,154 shares of the Company’s common stock, $0.001 par value per share (the “Shares”), which are to be offered and sold pursuant to the Company’s 2006 Stock Incentive Plan, as amended (the “Plan”).
Cyclodextrin enabled meds are being approved routinely and judged best as they stabilize the meds longer and without the negatives of current solubilizers. Approval is assured.